Clinical Trials Manager
I joined SITU (NDS) in November 2014 as the Clinical Trials Manager/Operational Lead. I am responsible for managing the portfolio of surgical trials and trial managers.
I obtained a PhD degree in Non-Viral Gene Therapy from the School of Chemistry, University of Birmingham. After which I worked as a formulation scientist at Aphton Corporation and then moved to lead a formulation team at Glide Pharma. During my time at Glide Pharma (http://glide-technologies.com) I was highly involved in setting up and running two Phase 1 CTIMP clinical trials including the GMP manufacture of the IMP. I joined Oxford University in 2010, to manage a multi-centre vasculitis study called TABUL which was funded by NIHR HTA programme (CI - Prof Raashid Luqmani, NDORMS, http://www.nets.nihr.ac.uk/projects/hta/086401 ), after successfully completion of recruitment and analysis phase in 2014, I decided to move to NDS. I am also a member of the Oxford C Ethics Committee since January 2013.
Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
Goodfellow N. et al, (2017), RMD open, 3, e000353 - e000353
Setting up clinical research studies in the National Health Service in England
Whitburn J. et al, (2017), Journal of Clinical Urology, 10, 145 - 147
HISTOLOGY FINDINGS IN GIANT CELL ARTERITIS (GCA) AND THEIR RELATIONSHIP WITH THE ULTRASOUND RESULTS: ANALYSIS OF DATA FROM THE TABUL STUDY (TEMPORAL ARTERY BIOPSY VS ULTRASOUND IN DIAGNOSIS OF GIANT CELL ARTERITIS)
Ponte CB. et al, (2017), RHEUMATOLOGY, 56, 56 - 57
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.
Luqmani R. et al, (2016), Health technology assessment (Winchester, England), 20, 1 - 238
VASCULAR ENDOTHELIAL GROWTH FACTOR AS AN AID TO DIAGNOSIS OF GIANT CELL ARTERITIS
Goodfellow N. et al, (2016), ANNALS OF THE RHEUMATIC DISEASES, 75, 435 - 436